BRIEF—MindMed appoints Francois Lilienthal as CCO

US clinical stage biopharma MindMed has appointed Francois Lilienthal as chief commercial officer (CCO).

Dr Lilienthal joins MindMed with over 20 years of experience leading the commercialization of novel medicines and driving multi-billion-dollar growth across diversified portfolios and businesses for big pharma including Merck & Co, Janssen Pharmaceutical Companies of Johnson & Johnson and Bristol Myers Squibb, among others.

After serving as a consultant for MindMed over the past six months, Dr Lilienthal will transition into a full-time member of a growing team comprised of former big pharma executives making the transition to advance the development of drugs at the cutting edge of neuropsychiatry.

Dr Lilienthal’s experience successfully leading the commercialization and global launch of products in a highly complex regulatory environment will be critical as MindMed advances its pipeline of psychedelic-derived therapies and initiates the first commercial study of LSD in more than 40 years.